— Know what they know.
Not Investment Advice

2268.HK

WuXi XDC Cayman Inc
1W: +1.6% 1M: -11.5% 3M: -15.3% YTD: -12.0% 1Y: +86.2%
HK$56.15 ($7.18)
-0.95 (-1.66%)
 
HKSE · Healthcare · Medical - Diagnostics & Research · HK$71.8B
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market CapHK$71.8B ($9.2B)
52W Range24.7-85.5
Volume4,331,693
Avg Volume4,219,705
Beta-2.10
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOJincai Li
Employees2,041
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2012-06-18
No. 11 Xinhui Ring Road
Wuxi
CN
About WuXi XDC Cayman Inc

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms